Catalyst Pharmaceuticals, Inc.
CPRXNASDAQHealthcare● Active
$31.28
+$0.01(+0.03%)
Market Cap$3.8B
P/E Ratio—
52W High$32.56
52W Low$19.05
Catalyst Pharmaceuticals, Inc. (CPRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CPRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
$0.74
Est. $0.64 · +15.6%
Revenue
$0.15B
Est. $0.15B · -0.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS🔥 11-Quarter EPS Beat Streak
CPRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.67 | — | — | — | $0.16B | — |
| ▲ Q2 FY2026 | May 11, 2026 | $0.64 | $0.74 | +15.6% | $0.15B | $0.15B | -0.1% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.42 | $0.68 | +61.9% | $0.15B | $0.14B | +6.8% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.51 | $0.68 | +33.3% | $0.15B | $0.14B | +4.0% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.58 | $0.68 | +17.2% | $0.15B | $0.14B | +4.4% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.53 | $0.68 | +28.3% | $0.14B | $0.13B | +7.8% |
| ▲ Q1 FY2025 | Feb 26, 2025 | $0.32 | $0.70 | +118.8% | $0.14B | $0.13B | +5.7% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.49 | $0.57 | +16.3% | $0.13B | $0.13B | -4.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.67
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
$0.74
EPS Est.
$0.64
EPS Surpr.
+15.6%
Revenue
$0.15B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.68
EPS Est.
$0.42
EPS Surpr.
+61.9%
Revenue
$0.15B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.68
EPS Est.
$0.51
EPS Surpr.
+33.3%
Revenue
$0.15B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.68
EPS Est.
$0.58
EPS Surpr.
+17.2%
Revenue
$0.15B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.68
EPS Est.
$0.53
EPS Surpr.
+28.3%
Revenue
$0.14B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
$0.70
EPS Est.
$0.32
EPS Surpr.
+118.8%
Revenue
$0.14B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.57
EPS Est.
$0.49
EPS Surpr.
+16.3%
Revenue
$0.13B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.57 | $0.59 | $0.61 | 1 |
| Q3 FY2027 | $0.55 | $0.57 | $0.59 | 1 |
| Q2 FY2027 | $0.53 | $0.55 | $0.57 | 1 |
| Q1 FY2027 | $0.54 | $0.56 | $0.58 | 1 |
| Q4 FY2026 | $0.46 | $0.48 | $0.50 | 1 |
| Q3 FY2026 | $0.44 | $0.48 | $0.52 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +15.6% | $31.15 | $31.15 | +0.00% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +61.9% | $24.19 | $24.86 | +2.77% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +33.3% | $21.34 | $21.38 | +0.19% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +17.2% | $22.22 | $21.79 | -1.94% |
| ▲ Q2 FY2025 | May 7, 2025 | +28.3% | $23.06 | $23.46 | +1.73% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +118.8% | $20.80 | $20.58 | -1.06% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +16.3% | $21.96 | $22.71 | +3.42% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +33.3% | $16.19 | $16.23 | +0.25% |
Q2 FY2026+0.00%
Report Date
May 11, 2026
EPS Beat/Miss
+15.6%
Price Before
$31.15
Price After
$31.15
Q1 FY2026+2.77%
Report Date
Feb 25, 2026
EPS Beat/Miss
+61.9%
Price Before
$24.19
Price After
$24.86
Q4 FY2025+0.19%
Report Date
Nov 5, 2025
EPS Beat/Miss
+33.3%
Price Before
$21.34
Price After
$21.38
Q3 FY2025-1.94%
Report Date
Aug 6, 2025
EPS Beat/Miss
+17.2%
Price Before
$22.22
Price After
$21.79
Q2 FY2025+1.73%
Report Date
May 7, 2025
EPS Beat/Miss
+28.3%
Price Before
$23.06
Price After
$23.46
Q1 FY2025-1.06%
Report Date
Feb 26, 2025
EPS Beat/Miss
+118.8%
Price Before
$20.80
Price After
$20.58
Q4 FY2024+3.42%
Report Date
Nov 6, 2024
EPS Beat/Miss
+16.3%
Price Before
$21.96
Price After
$22.71
Q3 FY2024+0.25%
Report Date
Aug 7, 2024
EPS Beat/Miss
+33.3%
Price Before
$16.19
Price After
$16.23
Avg Beat Reaction+0.67%
Beat Rate8 / 8 quarters
Largest Move+3.42% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CPRX ends December
Catalyst Pharmaceuticals, Inc. (CPRX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $0.74 — beating the analyst consensus of $0.64 by +15.6%. CPRX has beaten EPS estimates for 11 consecutive quarters. The next CPRX earnings date is expected around September 1, 2026.
Each quarter, investors track CPRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CPRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CPRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CPRX earnings · 5 questionsCatalyst Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. CPRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CPRX historically reports after market close (AMC).
CPRX earnings datewhen is CPRX earningsCPRX next earnings datewhen does CPRX report earningsCPRX earnings calendar
▸ Source: FMP · Catalyst Pharmaceuticals, Inc. SEC filings · US GAAP · Catalyst Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026